{"id":65319,"date":"2021-11-17T09:19:03","date_gmt":"2021-11-17T09:19:03","guid":{"rendered":"https:\/\/www.artefact.com\/?post_type=cases&p=65319"},"modified":"2024-09-20T17:39:23","modified_gmt":"2024-09-20T16:39:23","slug":"carnot-calym-institute-fighting-against-lymphoma-with-artificial-intelligence","status":"publish","type":"cases","link":"https:\/\/www.artefact.com\/es\/cases\/carnot-calym-institute-fighting-against-lymphoma-with-artificial-intelligence\/","title":{"rendered":" El Instituto Carnot CALYM<\/span> Lucha contra el linfoma con inteligencia artificial"},"content":{"rendered":"

<\/span><\/a><\/span>

Read our MEDIUM article about: “How did we use computer vision to help medical experts diagnose Follicular Lymphoma?”<\/u><\/p>\n<\/div>

<\/span><\/div>

.<\/p>\n<\/div><\/div><\/div><\/div><\/div>

Artefact, Microsoft and the Carnot CALYM Institute combined their expertise to build a Lymphoma Data Hub enabling researchers to leverage AI for accelerated early-stage diagnosis and therapeutic innovation.<\/p>\n<\/div>

A technology partnership to improve lymphoma diagnosis and treatment<\/h2><\/div>

Artefact transforms data and AI into value and impact not only for clients, but for humanitarian causes as well. The Artefact 4 Good<\/b> programme gives our employees the chance to contribute to meaningful projects. Microsoft\u2019s Share AI <\/b>skills sponsorship programme allows employees to do the same. The Carnot CALYM Institute<\/b>, an international academic research consortium, constantly seeks new ways to fight against lymphoma. Members from all three organisations joined together to see how AI could be used to identify new avenues of research<\/b>.<\/p>\n<\/div>

Context and challenges: what lymphoma is and how AI can help<\/h2><\/div>

Lymphoma is a blood cancer that begins in infection-fighting cells (lymphocytes) of the immune system. It is the most common blood cancer and the 6th most frequent cancer <\/b>worldwide, with some 80 sub-types. Due to their heterogeneity<\/b>, lymphomas are difficult to diagnose and require different therapeutic strategies.<\/p>\n

Because AI can analyse and integrate massive amounts of data, CALYM believes it can play a major role all along the innovation chain in R&D in Health, from disease characterisation <\/b>and diagnosis <\/b>to drug development <\/b>and personalised therapeutic strategies.<\/b><\/p>\n<\/div>

\u201cAI can safely accelerate product development and time to market for new medical treatments which can traditionally take years or even decades.\u201d<\/div>\n<\/div>
Vincent Luciani, CEO, Artefact<\/div>\n<\/div>

For the Lymphoma Data Hub project, CALYM already had assets to facilitate AI integration:<\/p>\n<\/div>